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Chronic glial activation is characterized by increased numbers of activated glial cells, secreting free 
radicals and cytotoxic cytokines, subsequently causing neuronal damage. In order to investigate the 
anti-inflammatory activity of Longvida® Optimised Curcumin (LC), we fed 500 ppm of LC to 2-month-
old wild type and GFAP-IL6 mice for 6 months. LC feeding led to a significant reduction in the number 
of Iba-1+ microglia by 26% in the hippocampus and by 48% in the cerebellum, GFAP+ astrocytes by 
30%, and TSPO+ cells by 24% in the hippocampus and by 31% in the cerebellum of the GFAP-IL6 
mice. The morphology of the cells was assessed and LC significantly decreased the dendritic length of 
microglia and the convex area, convex perimeter, dendritic length, nodes and number of processes 
of astrocytes in the hippocampus while decreasing the soma area and perimeter in the cerebellum, 
in LC-fed GFAP-IL6 mice. In addition, LC feeding increased pre- and postsynaptic protein levels and 
improved balance measured by Rotarod. Together, these data suggest that LC is able to attenuate the 
inflammatory pathology and ameliorate neurodegeneration and motor deficits in GFAP-IL6 mice. For 
patients with neuro-inflammatory disorders, LC might potentially reverse the detrimental effects of 
chronic glial activation.
In a healthy brain, microglia and astrocytes play a key role in the normal function of the central nervous system 
(CNS). The inflammatory response is mediated by the activated microglia, which is considered as the hallmark of 
neuroinflammation. The chronic activation of microglia leads to neuronal damage through the release of various 
cytotoxic molecules such as cytokines, reactive oxygen intermediates, and proteinases1. Microglia are involved 
in neural development including through phagocytosis of apoptotic cells. They also influence the function of 
neurons and their progenitor cells2. Astrocytes regulate synaptic transmission, for example through re-uptake of 
neurontransmitters such as glutamate, and support neurons with metabolic substrates such as gluthathione and 
lactate3.
Chronic microglial activation, or neuroinflammation, has been described in many neurodegenerative diseases 
including chronic traumatic encephalopathy, amyotrophic lateral sclerosis, Parkinson’s (PD) and Alzheimer’s dis-
ease (AD)4. For sporadic AD, surmounting histological evidence points to chronic microglial activation as a 
part of the disease process1,5. Chronic microglial activation describes long lasting, CNS-specific, aberrant glial 
responses that do not reproduce the classic characteristics of inflammation although they do contribute to neu-
rodegeneration6. To further support the role of neuroinflammation in AD, genome-wide association studies have 
identified a variety of inflammation-relevant genes that are associated with AD including clusterin (CLU), com-
plement receptor 1 (CR1) and triggering receptor expressed on myeloid cells 2 (TREM2)7. The role of the micro-
glial receptor TREM2 is to activate phagocytosis or microglial survival, and its link to AD is considered one of the 
strongest supporting arguments for the role of neuroinflammation in AD.
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The progress of neuroinflammation is characterized by both increased microglia numbers and altered mor-
phology. Under normal physiological conditions, microglia are designated as “resting” while the reactive mor-
phology is termed “activated.” Under physiological conditions, microglial shows long, delicate branched processes 
oriented radially to a small elliptical soma. However, they are never in a real resting state and play a critical 
constitutive role in scanning the environment8. In diseased tissue, due to injury or neuroinflammatory stimuli, 
microglia appear quite different, and go into an “activated state” with enlarged cell bodies, shortened and fewer 
processes and, a phagocytic appearance. Apoptotic cells, lipopolysaccharide, inflammatory cytokines or aggre-
gated proteins could trigger microglial cells in vitro to retract their processes and adopt amoeboid-like morpholo-
gies sometimes termed as “de-ramified microglia”9–11. While an acute microglia response can often resolve, under 
diseased conditions, microglia can remain in permanent chronic activation.
To histologically identify microglia, some of the most commonly used microglia markers are Iba-1 (ionized 
calcium binding adaptor molecule 1) and TSPO (translocator protein 18 kDa). Iba-1 is a microglia/macrophage 
specific calcium binding protein, while TSPO is a mitochondrial translocator protein predominantly expressed 
in the microglia, astrocytes, and macrophages in the blood vessels in the nervous system, specifically in the outer 
mitochondrial membrane of injured or activated cells12–14.
Astrocytes are the most abundant cell type of the CNS, playing a major role in brain homeostasis, providing 
metabolites and growth support to neuron synapse formation and plasticity and regulating the extracellular bal-
ance of ions and fluids15. Astrocytes are activated in response to neural insults, such as neuroinflammation and 
release cytokines, ILs, NO, and other potentially cytotoxic molecules16,17. Astrocytes respond to CNS challenges 
and the activated astrocytes are a hallmark of neuroinflammation which is characterized by high-level expression 
of glial fibrillary acidic protein (GFAP)18. Astrocytes display a bushy or spongiform morphology with very fine 
processes19, and when activated, they exhibit striking increases in GFAP immunoreactivity and in the number 
and length of GFAP-positive processes20.
In this study, we have used the GFAP-IL6 mouse which has been shown to be an established model of chronic 
glial activation and subsequent neurodegeneration. CNS-targeted production of pro-inflammatory cytokines 
including IL-121, IL-622 or TNF-α23 is a controlled way to initiate chronic glial activation. In the GFAP-IL6 mouse 
model, the trigger is the brain specific production of the cytokine IL6 by astrocytes (GFAP-IL6), resulting in both 
microglia and astroglia activation. Campbell et al., observed impairment of motor function and cognitive skills 
in hemizygous GFAP-IL6 mice at 12 months (homozygous GFAP-IL6 mice have a life span of <12 months), with 
cognitive decline, that were tested in a “conditioned avoidance response in a discriminated Y-maze” task24.
Our earlier investigation has established that in the GFAP-IL6 mice, fine motor skills already deteriorate from 
6 months of age on, accompanied by significantly increased micro- and astroglia numbers in both the cerebellum 
and the hippocampus25. In addition, synaptic deficits (synaptophysin, PSD95) were also observed in GFAP-IL6 
mice compared to the WT mice from 14 months onwards, indicating impaired synaptic transmission25. The aim 
of this study was to investigate the effects of LC on microglia and astroglia numbers as well as the glial morphol-
ogy in the GFAP-IL6 mouse, in parallel with motor function.
To test if chronic neuroinflammation could be reduced by pharmacotherapy, in this study, we used the main 
ingredient of the spice turmeric (Curcuma longa), curcumin, which is a cytokine suppressive anti-inflammatory 
drug (CSAID). CSAIDs have a broad range of anti-inflammatory effects and target the pro-inflammatory AP1 
and NF-κB signaling pathways and inhibit the expression of many pro-inflammatory cytokines in the low µM 
range26. Curcumin was shown to down-regulate the expression of cyclooxygenase-2 (COX-2), inducible nitric 
oxide synthase (iNOS), TNF-α, IL-1, -2, -6, -8, and -12. It inhibits IL-6 mediated signalling via inhibition of 
IL-6 induced STAT3 phosphorylation and consequent STAT3 nuclear translocation27, and interferes with the 
first signalling steps downstream of the IL-6 receptor in microglial activation4. To improve the bioavailability of 
curcumin, highly bioavailable curcumin formulations (encapsulated in lipid-based matrices such as liposomes 
and micelles) have been developed. One of these formulations is Longvida® Optimised Curcumin (LC) (Verdure 
Sciences Inc.) which can achieve µM concentrations in the rodent brain28,29. Human clinical trial data indicate 
that curcumin might exert effects in the CNS, but evidence for its effects on chronic microglial and astroglia acti-
vation in the CNS are still limited.
This study set out to evaluate the effects of LC on the numbers and morphology of both astrocytes and micro-
glia as well as markers of synaptic connectivity and motor function in the GFAP-Il6 mice.
Results
LC did not significantly affected the rate of body weight gain of the mice. To make sure that 
the animals were consuming enough LC containing pellets and gaining weight throughout the study, we fol-
lowed their body weight weekly for 13 weeks. We found no significant changes in the body weight of the male 
mice between genotypes and diets, using a three-way ANOVA analysis. The animals were definitely gaining 
weight, supported by the significant time effect [F(1.712, 47.94) = 147.0, p < 0.0001], while diet [F(1, 28) = 1.86, 
p = 0.182] or genotype [F(1, 28) = 0.042, p = 0.83] alone did not have a significant effect on the body weight of 
the animals (Fig. 1A). We also found a significant interaction between time and diet [F(12, 336) = 2.53, p = 0.003] 
for the male animals.
The body weight of females was analyzed separately by a three-way ANOVA as well. We found also a strong 
effect of time [F(2.208, 79.48) = 169.1, p < 0.0001] on the weight gain of the animals, however, we also noticed a 
significant effect of genotype [F(1, 36) = 12.46, p = 0.001], with no interaction between these variables. Further, 
we investigated the different genotype groups, using two-way ANOVA, and found in the case of the wild type 
females, the diet had a significant effect [F(1, 18) = 9.57, p = 0.006], resulting in slightly higher body weight 
throughout the study (Fig. 1B).
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LC significantly decreased the Iba-1+ microglia numbers in the hippocampus and cerebel-
lum. In order to test the genotype differences between wild type (WT) and GFAP-IL6 normal food-fed mice, 
and the effect of LC on the microglial number on both wild type and GFAP-IL6 mice, immunohistochemistry 
and stereological counting of Iba-1+ microglia were performed in the hippocampus and cerebellum in control 
and LC-fed cohorts.
Using two-way analysis of variance (ANOVA) on our cohorts, a significant difference was found between the 
groups [F(3,16) = 35.10, p < 0.0001] in the hippocampus, where the wild type mice had 184,706 ± 19,037 Iba-1+ 
microglia, and wild type LC-fed mice had slightly (16.53%) less (156,498 ± 10,762) (Fig. 2A,B,E). In contrast, 
the GFAP-IL6 mice had 383,588 ± 12,253 Iba-1+ microglia, which was significantly reduced to 295,666 ± 31,017 
(25.88%) in LC-fed mice (p < 0.02) (Fig. 2C–E).
In the cerebellum, a significant difference was found between the groups [F(3,23) = 16.72, p < 0.0001]. The 
wild type mice had 156,454 ± 33,721 Iba-1+ microglia which was slightly, but not significantly increased in wild 
type LC-fed mice (222,026 ± 7,555) (Fig. 3A,B,E). The GFAP-IL6 mice had 847,456 ± 46,120 Iba-1+ microglia, 
which was significantly downregulated (by 48%) in LC-fed GFAP-IL6 mice (439,038 ± 49,423) (p < 0.0001) 
(Fig. 3C–E).
LC downregulated the number of TSPO+ cells in GFAP-IL6 mice in the cerebellum but not in 
the hippocampus. TSPO is a translocator protein expressed on the outer mitochondrial membrane. It is 
Figure 1. Weight change of animals during the 26 weeks of feeding. (A) Weight change of male mice showed no 
significant differences between groups. (B) We found significant (p = 0.006) differences between the wild type 
normal and LC diet female groups, with the LC fed animals being heavier. The weight of the GFAP-IL6 animals 
was not significantly affected by diet.
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increased in response to injury and inflammation30. In order to investigate the genotype difference between the 
wild type and GFAP-IL6 normal food-fed mice, and to test the effect of LC on TSPO+ microglia in both wild 
type and GFAP-IL6 mice, immunohistochemistry and stereological counting of the TSPO positive microglia/
macrophages was performed.
In the hippocampus, a significant difference was observed between the groups [F(3,10) = 30.80, p < 0.0001]. 
The wild type mice had 6,626 ± 3,952 TSPO+ microglia, which was comparable to the numers of the LC-fed wild 
type mice (6,755 ± 1,730) (Fig. 4A,B,E). In contrast, GFAP-IL6 normal fed mice had 236,098 ± 28,005 TSPO+ 
microglia, which were reduced by 24.46% in LC-fed GFAP-IL6 mice (184,624 ± 23,174) (p > 0.1) (Fig. 4C–E).
In the cerebellum, a significant differenence was found between the groups [F(3,10) = 23.89, p < 0.0001]. 
Wild type mice had 18,108 ± 2,933 TSPO+ microglia, which were only slightly decreased by 5.73% in LC-fed 
wild type mice (17,098 ± 4,161) (p > 0.1) (Fig. 5A–B,E). GFAP-IL6 mice on a normal diet had 364,942 ± 28,577 
TSPO+ cells, which was significantly downregulated by 31.37% in the LC-fed GFAP-IL6 group (265,979 ± 55,791) 
(p < 0.005) (Fig. 5C–E). The stereological data of both Iba-1 and TSPO in the hippocampus and the cerebellum 
is summarized in Table 1.
Figure 2. Representative photomicrographs of immunohistochemical staining of the hippocampus showing 
decreased numbers of microglia (Iba-1+ cells) in the GFAP-IL6 LC-fed mice compared to their regular diet-
fed counterparts. (A–D) Images are representative of at least six animals per group (n = 6). Magnification 10× 
objective field, scale bar = 500 µm and 100 µm in inserts. (E) Graphical representation of total Iba-1+ count in 
the hippocampus. The graph represents the mean ± SEM and significant differences were determined using a 
two-way ANOVA (**p < 0.0015).
Figure 3. Representative photomicrographs of immunohistochemical staining for the microglia (Iba-1+ cells) 
of the cerebellum showing the LC feeding has significantly reduced the number of microglia in the GFAP-IL6 
LC-fed animals. (A–D) (Magnification 10× objective field, scale bar = 500 µm and 100 µm in inserts). Images 
are representative of at least six animals per group (n = 6). (E) Graphical representation of total Iba-1+ count 
in the cerebellum. The graph represents the mean ± SEM and statistical analyses were applied using a two-way 
ANOVA (****p < 0.0001, **p < 0.05).
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Figure 4. Representative photomicrographs of immunohistochemical staining for the microglia (TSPO+ cells) 
of the hippocampus showing that LC feeding has significantly increased the number of TSPO+ microglia in the 
GFAP-IL6 LC normal-fed animals. (A–D) (Magnification 10× objective field, scale bar = 500 µm and 100 µm in 
inserts). Images are representative of at least six animals per group (n = 6). (E) Graphical representation of total 
TSPO+ count in the hippocampus. The graph represents the mean ± SEM and the percentage differences were 
determined using a two-way ANOVA (p < 0.19).
Figure 5. Representative photomicrographs of immunohistochemical staining for the microglia (TSPO+ cells) 
of the cerebellum showing that LC feeding has significantly reduced the number of TSPO+ microglia in the 
GFAP-IL6 LC-fed animals. (A–D) (Magnification 10× objective field, scale bar = 500 µm and 100 µm in inserts). 
Images are representative of at least six animals per group (n = 6). (E) Graphical representation of total TSPO+ 
count in the cerebellum. The graph represents the mean ± SEM and significant differences were determined 
using a two-way ANOVA (***p < 0.001, *p < 0.05).
Genotype Diet
Iba-1 
hippocampus Iba-1 cerebellum
TSPO 
hippocampus TSPO cerebellum
GFAP 
hippocampus
Wild type Normal food 184,706 ± 19,037 156,454 ± 33,721 6,626 ± 3,952 18,108 ± 2,933 211,968 ± 11,730
Wild type LC 500 ppm 156,498 ± 10,762 222,026 ± 7,555 6,755 ± 1,730 17,098 ± 4,161 161,441 ± 19,648
GFAP-IL6 Normal food 383,588 ± 12,253 847,456 ± 46,120 236,098 ± 28,005 364,942 ± 28,577 372,850 ± 36,861
GFAP-IL6 LC 500 ppm 295,666 ± 31,017 439,038 ± 49,423 184,624 ± 23,174 265,979 ± 55,791 264,105 ± 24,115
Table 1. Stereological counting summary of the Iba-1, TSPO positive microglia in the hippocampus and the 
cerebellum. All values are presented as mean ± SEM.
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LC decreased the number of GFAP+ astrocytes in the hippocampus. In order to quantify the num-
ber of astrocytes, GFAP immunostaining and stereological quantification were performed to investigate the gen-
otype difference between wild type and GFAP-IL6 normal food-fed mice. Furthermore, the effect of LC on the 
elevated number of GFAP+ astrocytes in the wild type GFAP-IL6 mice was investigated in the hippocampus and 
cerebellum.
In the hippocampus, GFAP-IL6 mice had a significantly larger number of GFAP+ astrocytes (372,850 ± 36,861) 
compared to wild type mice (211,968 ± 11,730) (p < 0.0016) (Fig. 6A,C). In LC-fed wild type mice, the number 
of astrocytes reduced by 23% (161,441 ± 19 648) compared to their normal diet fed counterparts. Whereas, in 
LC-fed GFAP-IL6 mice, a significant reduction (30%) in GFAP+ astrocytes was observed (264,105 ± 24,115) com-
pared to the GFAP-IL6 normal food-fed mice (Fig. 6A–D,E).
In the cerebellum, the astrocytes and their processes were very closely packed, making stereological counting 
difficult, hence the numbers of GFAP+ cells were not serologically analyzed. However, high-level expression of 
GFAP protein was observed in GFAP-IL6 mice compared to wild type mice, located mostly but not exclusively in 
the gray matter of the cerebellum, with a strong presence of elongated microglia in the white matter and molec-
ular layer. The difference in the distribution of astrocytes between the wild type and GFAP-IL6 animals was sub-
stantial. Using qualitative observation, LC-fed groups appeared to have a comparatively low expression of GFAP 
protein compared to the GFAP-IL6 group (Fig. 7).
Effect of LC on microglial morphology in the hippocampus and cerebellum. In neuroinflamma-
tion or after brain injury, a de-ramification of microglia has been observed, in which the microglia enter an 
“activated state” characterized by swollen ramified cells with some larger and some shorter dendrites10. In order 
to investigate the genotype difference and the effect of the LC diet on Iba-1+ microglial cells, we analyzed the 
morphological features of the Iba-1+ microglia in the hippocampus and the cerebellum of the wild type and 
GFAP-IL6 mice, for both the normal-fed and LC-fed animals.
In the hippocampus, a difference in a few parameters between the genotypes was observed, as the Iba-1+ 
microglial cells of GFAP-IL6 normal-fed mice had significantly larger soma areas (57.25 ± 4.03 µm2) (p < 0.04), 
with smaller convex areas (1035.60 ± 79.12 µm2) (p < 0.0008) and convex perimeters (127.68 ± 4.39 µm) 
(p < 0.001) compared to those of wild type [soma areas (42.57 ± 3.82 µm2), convex areas (1535.63 ± 139.68 µm2) 
and convex perimeter (155.83 ± 6.11 µm)]. In addition, Iba-1+ microglia in wild type LC-fed mice had signif-
icantly larger dendritic length (281.94 ± 21.97 µm) (p < 0.014) than those of the wild type normal-fed mice 
(212.90 ± 10.23 µm). However, the Iba-1+ microglial cells of GFAP-IL6 LC-fed mice had a significantly larger den-
dritic length (266.83 ± 14.10) (p < 0.003) and number of nodes (9.25 ± 0.59) (p < 0.003) than that of GFAP-IL6 
normal-fed mice [Dendritic length (192.16 ± 14.58), number of nodes (6.43 ± 0.70)] (Fig. 8 A–H, Table 2).
In the cerebellum, a significant difference was observed in the genotype as the Iba-1+ microglial cells of 
GFAP-IL6 mice normal-fed had a significantly larger soma area (77.68 ± 7.89 µm2) (p < 0.0001), soma perim-
eter (37.21 ± 2.44 µm) (p < 0.0001) and a smaller convex area (1087.96 ± 15 µm2) (p < 0.015) and convex 
perimeter (137.57 ± 9.45 µm) (p < 0.026) compared to those of the wild type normal-fed mice [soma area 
(38.82 ± 2.80 µm2), soma perimeter (24.10 ± 0.82 µm) and small convex area (1750.71 ± 148.98 µm2), convex 
perimeter (171.42 ± 7.98 µm). Also, the Iba-1+ microglia in the wild type LC diet had a significantly larger den-
dritic length (265.30 ± 21.52 µm) (p < 0.048) than wild type normal-fed mice (199.55 ± 14.70). However, the Iba-
1+ microglial cells of GFAP-IL6 LC-fed mice had a significantly reduced soma area (50.18 ± 4.77 µm2) (p < 0.002), 
soma perimeter (28.10 ± 1.68 µm) (p < 0.001) and a higher number of nodes (8.07 ± 1.06) (p < 0.024) compared 
Figure 6. Representative photomicrographs of immunofluorescence staining for the astrocytes (GFAP+ cells) 
in the hippocampus showing the LC feeding has significantly reduced the number of GFAP+ astrocytes in the 
GFAP-IL6 LC-fed animals. (A–E) (Magnification 5× objective field, scale bar = 100 µm in 20× and 20 µm). 
Images are representative of at least six animals per group (n = 6). (E) Graphical representation of total GFAP 
count in the hippocampus. The graph represents the mean ± SEM and significant differences were determined 
using a two-way ANOVA (*p < 0.05, **p < 0.001).
7Scientific RepoRtS |         (2020) 10:2365  | https://doi.org/10.1038/s41598-020-58838-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
to that of GFAP-IL6 normal-fed mice [soma area (77.68 ± 7.89 µm2), soma perimeter (37.21 ± 2.44 µm) number 
of nodes (4.92 ± 0.65)] (Fig. 9A–H, Table 2).
In order to further the morphological characteristics of microglial cells from the hippocampus and the cer-
ebellum, a quantitative analysis termed as a Sholl analysis was applied which revealed some further variation in 
morphology between wild type and GFAP-IL6 normal-fed and LC-fed mice. In the hippocampus, there was no 
significant difference between wild type and GFAP-IL6 normal-fed mice observed in any parameter. The micro-
glia of wild type LC-fed mice has a significantly larger surface area (p < 0.0001), process volume (p < 0.0001), 
and process diameter (p < 0.0018) compared to that of wild type normal-fed mice. However, the microglia of 
LC-fed GFAP-IL6 mice have significantly larger processes in their length (p < 0.018) compared to GFAP-IL6 
normal-fed mice (Fig. 10A–F). In the cerebellum, there was not any genotype difference between wild type and 
GFAP-IL6 normal-fed mice. In wild type fed mice, the microglial cells have a significantly larger surface area 
(p < 0.0001), process volume (p < 0.0001), and process diameter (p < 0.0037) than that of wild type normal-fed 
mice (Fig. 11A–F).
In the hippocampus, a correlation analysis of overall microglial cell size with each morphological characteris-
tic revealed a significant correlation with the soma area, soma perimeter, number of nodes and primary dendrites 
in LC-fed GFAP-IL6 mice, which clearly revealed that the microglial cells of the GFAP-IL6 LC-fed mice poten-
tially increased the overall soma size and number of dendrites. In addition, the convex perimeter and dendritic 
length of each cohort increased with the increasing size of the entire cell. However, the rest of the parameters 
in the other cohorts remained consistent (Fig. 12A–F, Table 3). In the cerebellum, significant correlations were 
observed in all cohorts in convex perimeter and dendritic length with overall cell size, showing that the convex 
perimeter and the length of dendrites increased with the overall increase in microglial cells. Moreover, the num-
bers of nodes in GFAP-IL6 non-fed cohorts were increased with the overall increase in microglial cells. The other 
parameters remained consistent across the cohort, regardless of the cell size (Fig. 13A–F, Table 4).
Effect of LC curcumin on astrocytes morphology in the hippocampus. In inflammation, astrocytes 
are activated like microglial cells and undergo cellular hypertrophy which leads to the alteration of their size and 
shape. We, therefore, characterized the morphology of astrocytes in the hippocampus of wild type normal-diet, 
wild type LC-diet, GFAP-IL6 normal-diet, and GFAP-IL6 LC-diet mice (Fig. 14). In both wild type normal-diet 
and wild type LC-diet, we observed almost similar astrocytes and there were no significant differences. However, 
the astrocytes in the GFAP-IL6 normal-diet mice had a significantly larger dendritic length (275 ± 17.8 µm), 
number of processes (6.06 ± 0.51), convex area (1418 ± 128.3 µm2), convex perimeter (147.9 ± 6.01 µm) and num-
ber of nodes (7.62 ± 0.77) compared to the wild types. The LC diet significantly decreased the dendritic length 
(175.2 ± 14.54 µm) (p < 0.0001), number of processes (4.06 ± 0.23) (p < 0.0006), convex area (968.3 ± 74.04 µm2) 
Figure 7. Representative photomicrographs of immunofluorescence staining for the astrocytes (GFAP+ cells) 
in the cerebellum showing that LC-fed groups appeared to have a somewhat lower expression of GFAP protein 
compared to GFAP-IL6 group. (Magnification 5× objective field, scale bar = 100 µm in 5× and 20 µm in 
inserts). (A–D) Images are representative of at least six animals per group (n = 6).
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(p < 0.0056), convex perimeter (125.8 ± 4.24 µm) (p < 0.026), and number of nodes (5.43 ± 0.56) (p < 0.041) 
(Table 5).
Furthermore, we quantified the astroglial cells by Sholl analyses. In the same manner, this analysis did not 
reveal any significant changes between wild type normal-fed and LC-fed mice. We found that the LC significantly 
reduced the number of intersections and the length of processes compared to the normal-diet fed GFAP-IL6 mice 
(Fig. 15A–H).
We performed the bivariate correlation of morphological characteristics with overall astroglial cell size to 
investigate the impact of the size of astroglial cells on the structural parameters. We observed some positive cor-
relation of the astroglial cell size with some of the morphological parameters. The data revealed that the convex 
perimeter, dendritic length and the number of nodes increased significantly with the overall increase in the entire 
cell structure (Fig. 16A–H, Table 6).
Figure 8. Effect of LC on microglial morphology in the hippocampus. (A) The representative images of 
microglia immunostained for Iba-1 in the hippocampus showing that the Iba-1+ microglial cells of GFAP-IL6 
LC-fed mice had a significantly reduced soma area, soma perimeter and a higher number of nodes than that 
of GFAP-IL6 normal-fed mice. Scale bar 10 µm. (B–H) Graphs showing the morphological changes in Iba-1+ 
microglia. Two-way ANOVA, Tukey’s post-test, mean ± SEM (*p < 0.05, **p < 0.001).
Genotype Diet
Soma area (µm)2
Soma perimeter 
(µm) Convex 2D (area) (µm)2 Convex perimeter Total length of dendrites Number of Nodes
Number of 
Dendrites
H C H C H C H C H C H C H C
Wild type Normal food 42.5 ± 3.8 38.8 ± 2.8 24.8 ± 1.0 24.1 ± 0.8 1535.6 ± 139.6 1750.7 ± 148.9 155.8 ± 6.1 171.4 ± 7.9 212.9 ± 10.2 199.5 ± 14.7 5.4 ± 0.5 4.2 ± 0.5 5.0 ± 0.3 3.6 ± 0.3
Wild type LC food 43.4 ± 2.3 40.2 ± 2.2 25.5 ± 0.7 24.1 ± 0.7 1946.1 ± 132.5 2038.3 ± 191.5 181.9 ± 5.6 180.2 ± 8.5 281.9 ± 21.9 265.3 ± 21.5 5.8 ± 0.6 4.7 ± 0.7 5.0 ± 0.4 3.7 ± 0.2
GFAP-IL6 Normal food 57.2 ± 4.0 77.6 ± 7.8 29.8 ± 1.1 37.2 ± 2.4 1035.6 ± 79.1 1087.9 ± 150.0 127.6 ± 4.3 137.5 ± 9.4 192.1 ± 14.5 169.1 ± 17.5 6.4 ± 0.7 4.9 ± 0.6 5.9 ± 0.4 4.3 ± 0.3
GFAP-IL6 LC food 49.2 ± 4.4 50.1 ± 4.7 26.9 ± 1.2 28.1 ± 1.6 1230.8 ± 86.0 1348.8 ± 127.2 135.3 ± 4.2 151.1 ± 7.5 266.8 ± 14.1 212.3 ± 14.8 9.2 ± 0.5 8.0 ± 1.0 5.6 ± 0.4 3.6 ± 0.3
Table 2. Morphological analysis of Iba-1+ microglia in the hippocampus (H) and the cerebellum (C).
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LC feeding improved the levels of synaptophysin in the GFAP-IL6 mice. In order to investigate 
whether LC fed wild type and GFAP-IL6 mice showed any changes in synaptic markers expression compared to 
the normal diet-fed wild type and GFAP-IL6 mice at 8 months of age, the presynaptic marker synaptophysin and 
the postsynaptic marker PSD95 were quantified in cerebellum using Western blots.
For synaptophysin, a significant difference was found between the groups [F (3, 12) = 5.268, p = 0.001]. We 
found that synaptophysin levels of LC-fed GFAP-IL6 mice (1.78 ± 0.15) was significantly higher than the normal 
diet fed GFAP-IL6 mice (1.05 ± 0.07) (p = 0.03), restored to the level of the wild type mice. The levels of synap-
tophysin in LC-fed wild type mice (1.84 ± 0.15) were slightly higher compared to the normal diet fed wild type 
(1.71 ± 0.23) (Fig. 17A).
For PSD95, a significant difference was found between the groups [F (3, 12) = 4.854, p = 0.02]. A 59% of loss 
of PSD95 was observed in the normal diet-fed GFAP-IL6 mice (1.17 ± 0.07) compared to the normal diet-fed 
wild type (2.87 ± 0.61). These levels were found to increase in the LC-fed GFAP-IL6 mice (2.54 ± 0.19), but no 
significance was observed between the groups (Fig. 17B).
LC improved motor endurance loss measured by the Rotarod test in the GFAP-IL6 male 
mice. In order to investigate whether LC is able to ameliorate the motor function loss of the GFAP-IL6 mice 
we measured their performance on the Rotarod, which measures motor balance and muscle strength.
We examined the results by separating males and females and using 3 way ANOVAs at first. We found a sig-
nificant main effect of gender [F(1,111) = 7.296, p = 0.008], so we kept our analysis gender specific. For example, 
female GFAP-Il6 mice on normal diet were able to stay on the Rotarod for an average of 73 seconds (42%) longer 
than their male counterparts (Fig. 18).
LC supplementation in the male GFAP-IL6 mice improved their performance on the Rotarod. Multiple com-
parisons showing a significant difference in the GFAP-IL6 normal diet versus the GFAP-IL6 LC diet groups, with 
LC fed male GFAP-Il6 mice being able to stay an average of 92 seconds (63%) longer on the Rotarod than their 
non-supplented counterparts (p < 0.05) [F(1, 32) = 10.7, p = 0.03] (Fig. 18). We found no significant differences 
between the female control or LC fed GFAP-IL6 mice.
Figure 9. Effect of LC on microglial morphology in the cerebellum. (A) The representative images of microglia 
immunostained for Iba-1+ in the cerebellum showing that GFAP-IL6 LC-fed mice had a significantly reduced 
soma area, soma perimeter and a higher number of nodes than that of GFAP-IL6 normal-fed mice. (Scale bar 
10 µm). (B–H) Graphs showing the morphological changes in Iba-1+ microglia. Two-way ANOVA, Tukey’s 
post-test, mean ± SEM (*p < 0.05, **p < 0.001, ****p < 0.0001).
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Discussion
While it has been suggested that cytokine-suppressive anti-inflammatory drugs (CSAIDs) such as curcumin are 
able to downregulate chronic glial activation and protect against inflammation-induced neuronal damage in 
AD31, there have been relatively few investigations on how CSAIDs could potentially reduce chronic neuroinflam-
matory processes in preclinical settings. Identification of the effects of CSAIDs on chronic neuroinflammation 
Figure 10. The effect of LC on microglial cells in Sholl analysis in the hippocampus region. (A–F) The 
representative graphs showing that LC-fed GFAP-IL6 mice have significantly larger processes in length 
compared to GFAP-IL6 normal-fed mice and no significant difference between wild type and GFAP-IL6 
normal-fed mice in any parameter. wild type LC-fed mice have a significantly larger surface area, process 
volume, and process diameter than that of wild type normal-fed mice. However, the microglia of LC-fed 
GFAP-IL6 mice have significantly larger processes in length, which is observed in the peaks of the distributions 
of different morphological features. We call this “X at Ymax”. Two-way ANOVA test.
Figure 11. The effect of LC on microglial cells in Sholl analysis in the cerebellum region. (A–F) There was 
not any phenotype difference between wild type and GFAP-IL6 mice on a regular diet. However, we found 
significant differences between the wild type normal and LC-fed mice in terms of the microglial cells having a 
significantly larger surface area, process volume, and process diameter, which was observed in the peaks of the 
distributions of different morphological features. We call this “X at Ymax”. Two-way ANOVA test.
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Figure 12. Bivariate correlation analysis of overall microglial cell size with each morphological characteristic 
in the hippocampus showing significant correlation in LC-fed GFAP-IL6 mice. (A–F) Different morphological 
parameters in each cohort have been plotted against the convex hull area, showing significant correlation with 
the soma area, soma perimeter, number of nodes and primary dendrites in LC-fed GFAP-IL6 mice and a convex 
perimeter and increase in dendritic length of each cohort with the increasing size of the entire cell.
Soma area Soma perimeter Convex perimeter Dendritic length Nodes Primary dendrites
R2 Correlation R2 Correlation R2 Correlation R2 Correlation R2 Correlation R2 Correlation
WT NF 0.17 0.10 0.04 0.44 0.91 **** < 0.0001 0.26 *0.04 0.005 0.786 0.21 0.06
WT LC 0.17 0.17 0.16 0.18 0.70 ***0.0006 0.77 ***0.0001 0.010 0.749 0.02 0.59
GFAP-IL6 NF 0.13 0.15 0.22 0.06 0.90 **** < 0.0001 0.80 **** < 0.0001 0.161 0.122 0.23 0.05
IGFAP-IL6 LC 0.40 **0.008 0.51 **0.002 0.92 **** < 0.0001 0.58 ***0.0005 0.247 *0.05 0.28 *0.03
Table 3. Bivariate correlation of morphological characteristics with overall microglial cell size in the 
hippocampus in all the cohorts.
Figure 13. Bivariate correlation analysis of overall microglial cell size with each morphological characteristic 
in cerebellum. (A–F) Different morphological parameters in each cohort have been plotted against the convex 
hull area which shows significant correlations in all cohorts in the convex perimeter and dendritic length 
with overall cell size. However, the numbers of nodes in GFAP-IL6 non-fed cohorts increased with the overall 
increase in microglial cells.
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Cohorts Diet
Soma area(µm)2 
(Mean ± SEM)
Soma 
perimeter(µm) 
(Mean ± SEM)
Convex 2D (area) 
(µm)2(Mean ± SEM)
Convex 
perimeter(µm) 
Mean ± SEM)
Total length(µm) 
(Mean ± SEM)
Number of nodes 
(Mean ± SEM)
Number of 
dendrites 
(Mean ± SEM)
WT Normal food 15.88 ± 1.46 16.52 ± 0.79 885.3 ± 76.14 119.3 ± 5.82 163.2 ± 10.07 4 ± 0.45 4.81 ± 0.29
WT LC 21.22 ± 4.13 18.46 ± 1.35 1005 ± 79.18 129.7 ± 5.25 167.9 ± 8.34 4 ± 0.40 4.87 ± 0.23
GFAP-IL6 Normal food 14.68 ± 2.13 15.78 ± 1.14 1418 ± 128.3 147.9 ± 6.01 275 ± 17.8 7.62 ± 0.77 6.06 ± 0.51
GFAP-IL6 LC 16.66 ± 1.99 16.66 ± 1.07 968.3 ± 74.04 125.8 ± 4.24 175.2 ± 14.54 5.43 ± 0.56 4.06 ± 0.23
Table 4. Bivariate correlation of morphological characteristics with overall microglial cell size in the 
cerebellum.
Figure 14. Effect of LC on astrocyte morphology in the hippocampus showing significant decrease in overall 
astrocytes size in LC-fed GFAP-IL6 mice. (A) 3D reconstruction of astrocytes in wild type and GFAP-IL6 
in both showing that the LC diet treated and non-treated mice significantly decreased the dendritic length, 
number of processes, convex area, convex perimeter, and number of nodes Scale bar 10 µm. (B–H) Graphs 
showing the morphological changes in Iba-1+ microglia. Two-way ANOVA, Tukey’s post-test, mean ± SEM).
Soma area Soma perimeter Convex perimeter Dendritic length Nodes Primary dendrites
R2 Correlation R2 Correlation R2 Correlation R2 Correlation R2 Correlation R2 Correlation
WT NF 0.15 0.16 0.09 0.28 0.91 **** < 0.0001 0.53 **0.0028 0.008 0.7567 0.012 0.6987
WT LC 0.006 0.80 0.08 0.99 0.94 **** < 0.0001 0.54 **0.0059 0.01 0.6701 0.013 0.7196
GFAP-IL6 NF 0.0001 0.96 0.01 0.65 0.94 **** < 0.0001 0.96 **** < 0.0001 0.68 ***0.0003 0.014 0.9854
GFAP-IL6 LC 0.204 0.12 0.19 0.13 0.62 **0.0014 0.49 **0.0075 0.02 0.6396 0.002 0.8734
Table 5. Morphological analysis of GFAP+ astrocytes in the hippocampus.
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will facilitate the development of further anti-inflammatory medication to be potentially used in neurodegener-
ative diseases.
Despite its various pharmacological and therapeutic activities, the instability of curcumin at physiolog-
ical pH and its susceptibility to intestinal and hepatic metabolism have limited its therapeutic use. Although 
curcumin is well absorbed in glucuronidated and sulfated forms by the intestine and liver, which increases 
hydrophobicity, it therefore limits blood-brain barrier permeability and lowers bioavailability to the brain32,33. 
However, free curcumin is membrane permeable because it is lipophilic and fulfills the Rule of 5 characteristics of 
blood-brain barrier permeable molecules. To decrease the glucuronidation of curcumin, the use of piperine has 
Figure 15. LC increased the ramification of astrocytes in the hippocampus region. (A–F) A Sholl analysis 
confirmed a significant decrease in a number of intersections and processes length in LC-fed GFAP-IL6 
mice compared to normal food-fed GFAP-IL6. No significant changes occurred in wild type fed mice. LC 
significantly affects the inflamed astrocytes, which is observed in the peaks of the distributions of different 
morphological features being closer to the center compared to normal food-fed GFAP-IL6 mice. We call this “X 
at Ymax”. Two-way ANOVA test.
Figure 16. Bivariate correlation analysis of overall astrocyte size with each morphological characteristic in 
hippocampus. (A–F) Different morphological parameters in each cohort have been plotted against the convex 
hull area which revealed that the convex perimeter, dendritic length and the number of nodes increased 
significantly with the overall increase in the entire cell structure in LC-fed animals.
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been recommended34. To increase its stability and subsequent bioavailability, a number of different encapsulation 
approaches have been employed including the use of liposomal curcumin, including Longvida (LC) curcumin.
LC is a solid lipid curcumin particle form of dietary curcumin with high bioavailability and absorption, and 
in this study it has been used in the GFAP-IL6 mouse model, to investigate its therapeutic effects in chronic neu-
roinflammation. In the GFAP-IL6 mouse model, the murine IL-6 gene is expressed by astroglia under the tran-
scriptional control of the murine glial fibrillary acidic protein (GFAP) promoter, resulting in cytokine-induced 
low grade chronic glial activation, astrogliosis, and microgliosis22. Using this model, we have assessed the 
anti-inflammatory effect of LC after 4 months of feeding and compared the results with normal diet-fed animals, 
using both wild type and GFAP-IL6 animals on both diets.
The present study concluded that the number of Iba-1+ microglia is significantly increased in both the hippocam-
pus and the cerebellum in GFAP-IL6 normal-fed mice compared to the wild type normal-fed mice, which is in 
accordance with our previous report25. LC feeding significantly decreased the Iba-1+ microglia numbers by 25% in 
Soma area Soma perimeter Convex perimeter Dendritic length Nodes Primary dendrites
R2 Correlation R2 Correlation R2 Correlation R2 Correlation R2 Correlation R2 Correlation
WT non-fed 0.19 0.08 0.25 *0.04 0.86 **** < 0.0001 0.70 **** < 0.0001 0.47 **** < 0.0001 0.11 0.20
WT LC-fed 0.21 0.08 0.25 0.05 0.84 **** < 0.0001 0.63 ****0.0002 0.41 ***0.0002 0.02 0.55
IL-6 non-fed 0.01 0.69 0.0001 0.96 0.89 **** < 0.0001 0.78 **** < 0.0001 0.46 **** < 0.0001 0.02 0.59
IL-6 LC-fed 0.01 0.68 0.02 0.54 0.69 **** < 0.0001 0.87 **** < 0.0001 0.36 **** < 0.0001 0.008 0.73
Table 6. Bivariate correlation of morphological characteristics with overall astroglial cell size in the 
hippocampus.
Figure 17. LC feeding in the GFAP-IL6 mice restored the levels of presynaptic protein, synaptophysin to that 
of the wild type animals. Pre- and postsynaptic protein levels measured by Western blots in the wild type and 
GFAP-IL6 normal and LC-fed cohorts revealed that LC was able to restore the levels of synaptophysin to those 
of the wild type (*p < 0.05).
Figure 18. Rotarod performance is positively affected by the LC diet in the GFAP-IL6 male animals. Diet 
had a significant impact on the male animals when we measured their rotarod performance [F(1,32) = 10.7, 
p = 0.03], multiple comparisons showing a significant difference in the GFAP-IL6 normal versus LC diet groups 
(*p < 0.05).
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the hippocampus and by 48% in the cerebellum in the GFAP-IL6 animals. These reductions in the activated microglia 
numbers could indicate overall decreased levels of glial activation, meaning an improvement in the condition asso-
ciated with the neuroinflammatory process35. In accordance with our results, a previous study conducted in a mouse 
model of AD has compared the effect of solid lipid curcumin particles (SLCP) and normal curcumin. They reported 
that both SLCP and curcumin significantly reduced the Iba-1+ microglia numbers compared to the control36.
In the present study, we have investigated some of the morphological changes between ramified and 
non-ramified microglia. When investigating the hippocampus, we found that the Iba-1+ microglial cells of 
GFAP-IL6 mice normal-fed had significantly larger soma areas, small convex areas, and convex perimeter than 
those of wild type. The LC diet had significantly increased the dendritic length and number of nodes than that of 
GFAP-IL6 normal-fed mice. However, in the cerebellum, Iba-1+ microglial cells of GFAP-IL6 normal-fed mice 
had a significantly large soma area, soma perimeter and a smaller convex area and convex perimeter than those of 
the wild type non-fed mice. The LC diet had significantly reduced the soma area, soma perimeter and high num-
ber of nodes of the Iba-1+ microglial cells of GFAP-IL6 LC-fed mice compared to that of GFAP-IL6 normal-fed 
mice. Comparing our results to other studies, we found that a previous study performed on healthy adult mice 
has reported that ramified cells have small somas, and long and thin processes, which are necessary for active sur-
veillance of microglia microdomains37. However, when microglial cells are activated in response to the neuronal 
assault, injury or inflammation, they undergo morphological transformations, such as increased soma size and 
thickening of the processes8.
A recent study performed in mice has proved that solid lipid curcumin particles can reduce the aggregation 
and de-ramification of microglial cells in the hippocampus36, which is consistent with previous reports.
Our study has reported that LC has the potential to downregulate the TSPO+ microglia in chronic neuroin-
flammation. A recent study performed in the same mouse model found that the number of TSPO+ cells increased 
in GFAP-IL6 mice and it increased even more in Tenilsetam treated mice30. The present study has revealed that 
the TSPO+ microglia is significantly increased in both regions (hippocampus and cerebellum) of the brain in 
GFAP-IL6 normal-fed mice compared to the wild type normal-fed mice. After feeding the LC to the mice, the 
TSPO+ microglia numbers significantly reduced by 31% in the cerebellum and 24% in the hippocampus.
However, microglia were also shown to have neuroprotective properties, for instance in AD, and so reducing 
the numbers might worsen the disease38. Therefore, microglia numbers alone, without the rest of the pathological 
improvement, does not mean decreased chronic glial activation. Because of this, we also examined the motor 
functions of our cohorts and found that long-term LC supplementation improved the balance and motor coordi-
nation on the rotarod for the male GFAP-IL6 mice. Motor function impairment GFAP-IL6 mice in the rotarod test 
have been previously reported by our group25. IL-6 mediated motor function impairment has also been found in 
mouse models taking the rotarod test following experimental traumatic brain injury (TBI)39. Similar studies have 
provided evidence for IL-1 and TNF-α mediated motor function deficits in mice subjected to TBI40. Impaired 
rotarod performance has also been reported in mice with astrocyte-derived IL-3 expression in the brain41. Other 
studies have also found similar improvements in motor skills measured by the rotarod test after curcumin sup-
plementation. For example, curcumin feeding of 50, 100 and 200 mg/kg per os for 3 weeks in a mouse model 
of Parkinson’s disease, has shown to ameliorate rotarod test deficits in a dose-dependent manner compared to 
non-treated counterparts42. Daily oral feeding of mice with the inherited peripheral neuropathy model with cur-
cumin in 50 or 100 mg per kg bodyweight doses for 90 days has revealed improved rotarod performance compared 
to non-fed counterparts43. Single intrastriatal injection of a mouse model for brain oxidative damage with cur-
cumin (10–100 µg) or Theracurmin (30–300 µg) revealed improved rotarod performance of mice by both forms of 
curcumin in a dose-dependent manner44. However, single oral feeding of mice for the same model with curcumin 
(30–300 mg/kg) or Theracurmin (0.3–3 g/kg) improved rotarod performance in only the Theracurmin group.
This study reports that LC decreases the GFAP+ astrocytes and ultimately chronic neuroinflammation. A 
study performed in a mouse model of AD counted the number of GFAP+ cells in different brain areas, specifi-
cally in the CA1, the CA3, the dentate gyrus, the subiculum, the entorhinal cortex, and the striatum. The authors 
observed inhibition of GFAP+ cell expression in the normal curcumin and SLCP-treated mice36. This is consistent 
with our findings which showed that, in the hippocampus, GFAP-IL6 mice had a significantly larger number 
of GFAP+ astrocytes compared to wild type mice and in the LC-fed GFAP-IL6 mice, a significant reduction in 
GFAP+ astrocytes were observed by 30% compared to the GFAP-IL6 normal food-fed mice. A recent study using 
curcumin formulation reported that curcumin treatment decreased astrocyte activation36. Herein, a morpho-
logical assessment of astrocytes in the hippocampus shows that GFAP-IL6 normal-diet mice have a significantly 
larger dendritic length, number of processes, convex area, convex perimeter and number of nodes compared to 
the wild types. The LC diet significantly decreases the dendritic length number of processes, convex area, convex 
perimeter and number of nodes.
It has been shown that an increase in activated microglia leads to synaptic damage45,46, further leading to 
dysfunctional synaptic transmission in neurodegenerative diseases, measured by a significant loss of the pre- 
and post-synaptic proteins in the inflammatory state. Our results support this finding by estimating the levels of 
synaptic proteins (synaptophysin, PSD95) in the cerebellum of wild type and GFAP-IL6 mice (both normal-fed 
and LC-fed). We found that after LC treatment, 42% of synaptophysin and 59% of PSD95 protein levels were 
restored in the cerebellum of GFAP-IL6 mice. In correspondence with our results, others have also found that 
using curcumin on the APPswe/PS1dE9 double transgenic mouse model restores the quantity and structure of 
the synapses measured by western blots for the PSD95 hippocampal CA1 area, with the curcumin treatment 
increasing the expression of this protein47.
In addition, we found that the female mice fed with LC had an increased bodyweight. This was probably due 
to the fact, that they had a baseline bodyweight somewhat higher than the other female cohort group, which was 
still within the normal weight range. We were satisfied with the weight gain of all the groups fed with LC, showing 
no signs of food or taste aversion.
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With these reported results, our study has opened a window to further investigate this particular curcumin 
formulation and its mode of action on both microglia and astroglial activation. In the future, the effects of LC 
directly on cognitive decline and neuronal degeneration should be also investigated. The main potential limita-
tion of this study is that it did not investigate the molecular mechanisms of the inhibition of glial cells, hence the 
signal transduction mechanism pathways in which curcumin could have carried out its effects on glial cells is still 
unknown.
In summary, this study investigated the impact of Longvida® Optimised Curcumin formulation, against astro- 
and microglial cell activation and chronic neuroinflammation. We found that LC has the potential to ameliorate 
chronic microglia and astroglial activation by reducing increased glial cell numbers and restoring their mor-
phology towards the resting/ramified state. This study has provided strong evidence that LC has the potential 
to reduce chronic activation of microglia and astrocytes in the brain, and might be beneficial for preventing 
neurodegenerative disorders
Materials and Methods
Animals. Wild type (C57BL/6) and GFAP-IL6 mice of mixed genders weighing 20–30 g were housed in the 
animal facility of the School of Medicine, Western Sydney University under a temperature-controlled environ-
ment, with a normal 12 h/12 h light/dark cycle at 23 °C, 60 ± 10% humidity, and provided with food and water 
ad libitum. The experimental procedures were approved by Western Sydney University Animal Care and Ethics 
Committee (approval ID: A11393) and carried out in accordance with the rules established by the National 
Health and Medical Research Council of Australia. Heterozygous GFAP-IL6 mice and their non-transgenic litter-
mates (wild type C57BL/6) were used at the age of 2 months.
Grouping of animals and feeding with LC food pellets. In this long-term feeding study, animals were 
randomly assigned to 4 groups: Wild type C57BL/6, GFAP-IL6 mice fed with control food pellets and GFAP-IL6, 
GFAP-IL6 mice fed with LC diet (Table 7). The Longvida curcumin (LC) food pellets were supplied by Verdure 
Sciences Inc.; Noblesville, IN. The pellets consisted of Longvida® Solid Lipid Curcumin Particles (SLCP) with 
enhanced bioavailability. At the age of 2 months, the mice were put on feeding at one defined dose for the dura-
tion of 6 months. Animals were monitored, with their body weight and the amount of food consumed recorded. 
At the age of 8 months, the behavioral test was performed followed by perfusion for histology.
Evaluating body weight and motor function. Before the evaluation of motor function, we monitored 
the weight of the animals during the feeding and after the completion of the feeding protocol, respectively. To 
assess the coordination and balance in rodents, we used an accelerating, rotating 9 cm diameter rod apparatus 
(Ugo Basile, Biological Research Apparatus, Varese, Italy), and used “time to fall” as the readout. Each mouse was 
placed on the apparatus at a steady speed of 5 rpm. The speed was gradually increased from 5 rpm to 40 rpm over 
a period of 300 seconds, and the latency until the mouse fell off the rod was measured (with a maximum cut-off 
time of 300 secs). Each mouse was subjected to three trials a day with a 45-min inter-trial interval. Data presented 
were averaged of the best two scores across the three trials.
Histology and tissue sample preparation. For histological analysis, the tissue samples were prepared 
from all experimental cohorts. Mice were anaesthetized with Pentobarbitone (30–50 mg/kg IP (20–40 min. of 
anesthesia) and transcardially perfused with 30 ml of 0.9% normal saline using a peristaltic pump, followed by 
60 ml of 4% cold paraformaldehyde (Merck) (in 0.1 M phosphate buffer). Brains were harvested and post-fixed 
in 4% paraformaldehyde for 24 hrs at 4 °C, and then transferred to 30% sucrose (in 0.1 M PB solution) for cryo-
protection. After the brains sank to the bottom of the container, they were embedded and frozen with 6% gelatin. 
Fifty micrometer thick coronal sections were cut in six series using a Leica CM 1950 cryostat.
Immunohistochemistry. For bright field microscopy, immunohistochemistry assays were performed on 
every 6th section of the brains to identify microglial activation using microglia markers (Iba-1 and TSPO). All 
washing and incubation procedures were performed using 0.1 M PBS unless stated otherwise. The sections were 
washed 3 times and treated with 1% H2O2 before being incubated for 2 hrs in the blocking solution (2% goat 
serum) to block non-specific antigen binding sites. Then they were incubated in the primary rabbit-anti-Iba1 
antibody (1:500, Wako, # 019-19741) and rabbit-anti-TSPO (1:500, Merck, #ABC139) solutions for two days 
at 4 °C and subsequently in the secondary antibody (1:200, biotinylated goat anti-rabbit IgG; Life Technologies, 
#656140) for 2 hrs. The sections were washed 3 times and ABC solution (1:250, Vector Laboratories, # PK-6100) 
was applied for 2 hrs. Sections were then incubated in the developer solution containing 0.4 mg/ml DAB and 
0.0006% hydrogen peroxide until an optimal color developed. In the end, the sections were washed, mounted, 
dehydrated, coverslipped and images were captured with a Zeiss microscope (MBF Bioscience).
Cohorts Type of food
Number of mice used
Iba-1 GFAP TSPO
WT Normal food 5 6 3
GFAP-IL6 Normal food 7 6 6
WT LC (500 ppm) 7 6 3
GFAP-IL6 LC (500 ppm) 7 6 6
Table 7. Summay of the cohorts, type of diet and number of mice used.
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Fluorescence microscopy. Immunofluorescent staining against GFAP was performed on every 6th sec-
tion from the brains to identify astroglial activation using GFAP as an astroglial marker. The sections were 
washed with 0.1 M PBS in order to remove the gelatine and incubated in the primary rabbit-anti-GFAP antibody 
(1:500, Dako, #20023331) solution for one day at 4 °C followed by a fluorescence secondary antibody (1:200, goat 
anti-rabbit IgG, Alexa 488; Thermo Fisher Scientific, # 1853312) for 2 hrs. The sections were washed, mounted 
and coverslipped with a fluorescent mounting medium (Vector Laboratories, #H1400).
Stereological counting. The estimated number of glial cells in both the cerebellum and the hippocampus 
was counted on Iba1, TSPO and GFAP stained sections using the Zeiss AxioImager M2 microscope equipped 
with MBF Biosciences StereoInvestigator30. The contour of the cerebellum and the hippocampus was first drawn 
under the 2.5× objective. The size of the counting frame was 100 × 100 μm for the wild type in both the hip-
pocampus and the cerebellum, 60 × 60 μm for GFAP-IL6 non-fed mice as well as for LC mice. However, it 
was 80 × 80 μm in the case of TSPO counting. The counting grid was 1000 × 1000 μm for the cerebellum and 
800 × 800 μm for the hippocampus for the entire cohorts. The guard zone was 1 μm at the top and the bottom of 
the sections. Microglia and astrocytes were plotted on the screen using a marker as the focus moved from the top 
to the bottom of the sections using a 63x oil objective. This led to the Gunderson coefficient error of less than 0.1 
in all cases (m = 1).
Three-dimensional reconstruction of astrocytes. Samples were prepared as described above and the 
images were taken using a confocal ZEISS laser scanning microscope (LSM-5) with an argon laser and processed 
using the Zen 2009 software package. Z-stacks were captured using a 20 × objective, NA1.0 for reflective imaging, 
at a step size of 0.1um (unless specified otherwise). Reflective imaging was achieved using the 488 nm wavelength. 
For the three-dimensional reconstruction of astrocytes, Neurolucida 360 (MBF Bioscience) software was used. To 
better identify the objects and provide greater accuracy, all the images were taken using a 20× high power objective 
with the laser scanning confocal microscope. A total of 16–20 cells in the hippocampus of the brain were traced in 
each experimental cohort and fully or partially reconstructed (only soma). After importing Z-stacks to Neurolucida 
360 software, astrocytes were manually reconstructed along required planes, getting a 3D image of each cell.
Analysis of reconstructed cells. Morphometric data of each astrocyte were extracted by the software and 
thus, each reconstructed cell was subject to multiple parameters. The soma area, soma perimeter, convex 2D 
area, convex perimeter, total length of all processes, total volume of all processes, total density and number of 
nodes (branch points) and dendrites of all the processes were measured. In order to determine changes in the 
size of the cells in relation to distance from the cell soma, a Sholl analysis was performed for each astroglial cell. 
Z-stack images of live astrocytes were condensed into a maximum intensity and the Sholl analysis was applied 
in Neurolucida 360 software. Concentric circles (radii) originating from the soma were spaced 5 μm apart in 
this case. This analysis determined the number of intersections, process length (µm), the surface area of the cells 
(µm2), process volume (µm3), process diameter (µm) and the number of nodes of the cells for each radius.
Western blot. Western blot experiments were performed as described elsewhere25. In short, tissue samples 
from the cerebellum of mice brain were homogenized (10% w/v) in an ice-cold lysis buffer [100 mM Tris (pH 
7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton-x 100 (v/v) and 0.5% sodium deoxycholate] with 
freshly added protease (Thermo Fisher, Cat No: A32963) and phosphatase inhibitors (Sodium orthovanadate, 
sodium fluoride, staurosporine), using a motor-driven homogenizer (Thomas Scientific) on ice. The lysate was 
centrifuged at 14,000 rpm for 20 min at 4 °C and the total protein estimation of the supernatant was tested using 
the Bradford reagent (Bio-Rad) at 595 nm (UV-absorption). After protein quantification, tissue extracts (25 μg) 
were boiled in a Laemmli sample buffer at 95 °C for 10 mins, followed by 10% SDS-PAGE electrophoresis at 90 V 
for 1.5 hours, electro-transferred to nitrocellulose membranes for 2 hours at 100 V. Non-specific protein binding 
was blocked with 5% milk in 0.1% Tween TBS. Membranes were incubated overnight at 4 °C with a mouse mon-
oclonal antibody to PSD95 (0.5 µg/mL, # MABN68, Merck) or a mouse polyclonal antibody to Synaptophysin 
(1:500, # ab8049, Abcam) in 0.1% Tween TBS. Membranes were then washed and incubated for 1 hour with an 
HRP-conjugated secondary antibody (1:10,000) in 0.1% Tween TBS. Membranes were then washed and immu-
noreactivity was visualized with a chemiluminescence detection method (ECL, Merck Millipore) using Imagelab 
software (Biorad). Optical densitometry was performed on each targeted band (Synaptophysin: 38 kDa; PSD-95: 
95 kDa) using the computerized image analysis software ImageJ (NIH).
Statistical analysis. For all our behavioral analysis, at first a three-way ANOVA was used with the variable 
factors “age,” “genotype,” and “gender.” We did not detect any sex-effects (all p > 0.05) and therefore combined 
male and female data sets for further analysis using two-way ANOVA for “genotype” and “age” with Bonferroni 
correction for multiple comparisons. In line with Rothman48 and Perneger49, the data were not adjusted for mul-
tiple comparisons and were interpreted as such in the discussion. In the case of significant interactions between 
“genotype” and “age”, we split data by the corresponding factor. Histological quantification analysis results were 
analyzed by using two-way ANOVA with Bonferroni correction for multiple comparisons. Differences were 
regarded as statistically significant when p < 0.05. [(DFn, DFD) = F, p] indicating the value of the F-test, the 
degrees of freedom of the numerator and denominator and the significance, respectively, and were used to 
determine whether the factors significantly affected the result. A three-way ANOVA analysis was performed 
using SPSS 22.0 for Windows and a two-way ANOVA with multiple comparisons were performed with a Prism 
GraphPad (version 7). Statistical outliers were defined where the values were smaller or bigger than ±2.5 times of 
standard deviations from the overall mean. Western blot results were analyzed using one-way ANOVA. Results 
are presented as mean ± SEM.
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